Should Roivant’s Moderna Settlement Shift Investor Focus to Pipeline Execution Risks for Roivant Sciences (ROIV)?

Simply Wall St.03-28 03:04

In March 2026, several banks, including Bernstein and JPMorgan, updated their views on Roivant Sciences after a global settlement with Moderna over lipid nanoparticle technology. These analyst actions...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622914877?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-03-28 03:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622914877","market":"us","top_or_hot":-1,"title":"Should Roivant’s Moderna Settlement Shift Investor Focus to Pipeline Execution Risks for Roivant Sciences (ROIV)?","media":"Simply Wall St.","content":"<div>\n<p>In March 2026, several banks, including Bernstein and JPMorgan, updated their views on Roivant Sciences after a global settlement with Moderna over lipid nanoparticle technology. These analyst actions...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/should-roivants-moderna-settlement-shift-investor-focus-to-p\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Roivant’s Moderna Settlement Shift Investor Focus to Pipeline Execution Risks for Roivant Sciences (ROIV)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Roivant’s Moderna Settlement Shift Investor Focus to Pipeline Execution Risks for Roivant Sciences (ROIV)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-28 03:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/should-roivants-moderna-settlement-shift-investor-focus-to-p><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In March 2026, several banks, including Bernstein and JPMorgan, updated their views on Roivant Sciences after a global settlement with Moderna over lipid nanoparticle technology. These analyst actions...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/should-roivants-moderna-settlement-shift-investor-focus-to-p\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/should-roivants-moderna-settlement-shift-investor-focus-to-p","article_id":"2622914877","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/should-roivants-moderna-settlement-shift-investor-focus-to-p","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622914877","pubTimestamp":1774638299,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In March 2026, several banks, including Bernstein and JPMorgan, updated their views on Roivant Sciences after a global settlement with Moderna over lipid nanoparticle technology.\nThese analyst actions suggest the settlement is shifting attention away from legal risk and toward Roivant’s upcoming clinical trial milestones in pulmonary hypertension and non-infectious uveitis.\nWe’ll now examine how the Moderna settlement, seen as clearing a legal overhang, may influence Roivant’s existing...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4139":"生物科技","ROIV":"Roivant Sciences Ltd."},"translate_title":"Roivant的Moderna和解是否应该将投资者的注意力转移到Roivant Sciences(ROIV)的管道执行风险上？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":1.5},"content_text":"In March 2026, several banks, including Bernstein and JPMorgan, updated their views on Roivant Sciences after a global settlement with Moderna over lipid nanoparticle technology. These analyst actions suggest the settlement is shifting attention away from legal risk and toward Roivant’s upcoming clinical trial milestones in pulmonary hypertension and non-infectious uveitis. We’ll now examine how the Moderna settlement, seen as clearing a legal overhang, may influence Roivant’s existing investment narrative and risk profile. The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementRoivant Sciences Investment Narrative RecapTo own Roivant today, you need to believe its late stage pipeline in pulmonary hypertension, non infectious uveitis and autoimmune diseases can eventually justify ongoing losses and heavy R&D. The Moderna lipid nanoparticle settlement appears to reduce a key legal uncertainty, which in turn sharpens attention on upcoming clinical readouts as the most important short term catalysts. The biggest near term risk remains that one or more pivotal trials disappoint or are delayed, prolonging unprofitability. Among recent updates, Pulmovant’s February 2026 announcement that the Phase 2 PHocus trial of mosliciguat in PH ILD has fully enrolled stands out. With topline data guided for the second half of 2026, this program now looks like one of the clearest medium term clinical catalysts that investors can track against the backdrop of the resolved Moderna dispute and a cleaner legal risk profile. Yet while legal risks have eased, the real test investors should be aware of is whether upcoming trial results and cash burn trends will... Read the full narrative on Roivant Sciences (it's free!)Roivant Sciences’ narrative projects $1.4 billion revenue and $183.3 million earnings by 2029.Uncover how Roivant Sciences' forecasts yield a $33.25 fair value, a 22% upside to its current price.Exploring Other PerspectivesROIV 1-Year Stock Price Chart Some of the lowest ranked analysts were already modeling revenue rising about 53 percent annually to only US$73.0 million by 2029 and earnings of roughly US$11.8 million, highlighting a far more cautious view than consensus and raising the question of whether the Moderna settlement and shifting catalyst mix could soften or reinforce that pessimism.Explore 4 other fair value estimates on Roivant Sciences - why the stock might be worth as much as 22% more than the current price!Decide For YourselfDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Roivant Sciences research is our analysis highlighting 2 key rewards that could impact your investment decision.Our free Roivant Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Roivant Sciences' overall financial health at a glance.Searching For A Fresh Perspective?Opportunities like this don't last. These are today's most promising picks. Check them out now:Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.Find 61 companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622914877","isCrawlerRequest":true}